The ternary gene
Founded in 1992, Beijing Sanyuan Gene Pharmaceutical Co., LTD. (Sanyuan Gene) is the first company in China named after the proprietary technology of genetic engineering. The company is mainly engaged in the research, development, production and sales of modern biomedical products, and is a leading enterprise in the field of basic research and clinical application development of genetic engineering drugs in China.
Founded in 1992, Beijing Sanyuan Gene Pharmaceutical Co., LTD. (Sanyuan Gene) is the first company in China named after the proprietary technology of genetic engineering. The company is mainly engaged in the research, development, production and sales of modern biomedical products, and is a leading enterprise in the field of basic research and clinical application development of genetic engineering drugs in China. The company's main products are multi-dosage form and multi-specification recombinant human interferon α 1B, which is the first genetic engineering class A drug with independent intellectual property rights in China (National Class I new drug), with unique product advantages and huge clinical application potential. The product was developed by Academician Hou Yunde, the first chairman of the company and winner of the 2017 National Highest Science and Technology Award, and is the original genetic engineering drug in the world. This product has achieved a breakthrough in China's genetic engineering drugs from nothing to "zero". Through more than 20 years of research and development, the company has formed a rich portfolio of recombinant human interferon α 1B dosage forms. The clinical application covers many clinical departments such as infection department, pediatrics department and oncology department. Treatment of viral hepatitis, viral pneumonia, melanoma and other viral diseases and malignant tumors. The company's main product, recombinant human interferon α 1B, has been sold to more than 3,500 medical institutions in 31 provinces, autonomous regions and municipalities, and has been in the leading market share in mainland China for many years.
Sanyuan gene has strong research and development strength and has been adhering to independent innovation for many years, forming many innovative achievements and successfully realizing industrialization. The innovation achievements have been widely recognized by governments and competent departments at all levels. The company currently holds 52 domestic and foreign authorized patents, including 49 invention patents, and has obtained 12 drug registration certificates or drug re-registration approvals. The company has won the "High-tech Enterprise Certificate", "National Intellectual Property Advantage Enterprise Certificate", "National Scientific and Technological Achievements Key Promotion Project Technology Support Unit Certificate" and "Beijing Patent Demonstration Unit Certificate" and other qualifications. The company has been approved by the state and established academician expert workstation, doctor post-scientific research station and Beijing Engineering technology research center. The company's products have won the "National Key New Product Certificate", "Beijing Independent Innovation Product Certificate", "Zhongguancun National Independent Innovation Demonstration Zone New Technology and New Products (Service) certificate" and "Beijing Torch Project Certificate". In particular, the project of "development, production and application of genetically engineered human interferon alpha series products" led by recombinant human interferon α 1B was awarded the first prize of National Science and Technology Progress Award.
In May 2016, Sanyuan gene was listed in the National Stock Exchange system (NEEQ). In January 2021, the company successfully entered the selected layer of neeQ. As a representative of a listed company on Beijing Stock Exchange (BSE), Chairman of Sanyuan Gene made an honorary speech at the opening ceremony on November 15, 2021. The chairman and general manager of THE BSE sent a congratulatory letter to Sanyuan before the market opened: "On September 2, General Secretary Xi Jinping announced that he would continue to support the innovative development of small and medium-sized enterprises, deepen the reform of the New Third Board, set up the Beijing Stock Exchange, and create a position to serve innovative small and medium-sized business owners. General Secretary Xi Jinping's important instructions have pointed the way and provided guidance for us to follow. Under the care and great attention of the CPC Central Committee and The State Council, under the strong leadership of the CPC Committee of China Securities Regulatory Commission, and under the strong support and joint efforts of all parties, the Beijing Stock Exchange will soon open. On the occasion of the celebration, the Beijing Stock Exchange would like to extend warm congratulations to the first batch of listed companies!" .
As a joint actor, Southeast Capital has become the substantial joint major shareholder of SANYUAN Gene through Beijing Southeast Pharmaceutical Investment Holding Co., LTD. (Pharmaceutical Holding).
After listing, sANYUAN's shares were actively traded in the secondary market, and the stock price moved steadily higher. With the development of new drugs will be put into production and sales, it can be predicted that the market value of SANYUAN gene will have a leap of development, bringing considerable investment income to Southeast Capital.
Company website link: http://www.triprime.com/